Suspensions vaginal

The design of vaginal, rectal, and nasal irritation studies is less formalized, but follows the same basic pattern as the primary dermal irritation test. The rabbit is the preferred species for vaginal and rectal irritation studies, but the monkey and dog have also been used for these (Eckstein et al., 1969). Both the rabbit and rat have commonly seen use for nasal irritation evaluations. Defined quantities (typically 1.0 ml) of test solutions or suspensions are instilled into the orifice in question. For the vagina or rectum inert bungs are usually installed immediately thereafter to continue exposure for a defined period of time (usually the same period of hours as future human exposure). The orifice is then flushed clean, and 24 h after exposure it is examined and evaluated (graded) for irritation using the scale in Table 11.1. 

Conventional vaginal delivery systems include tablets, foams gels, suspensions, and pessaries. Mucoadhesive gel formulations based on polycarbophil have been reported to remain 3 to 4 days at the vaginal tissue, providing an excellent vehicle for the delivery of progesterone and nonoxynol-9 [66]. 

Flamycin 2-5 lac U (suspension topically as vaginal tablet and ointment)... 

Nystatin Mycostatin Nilstat others Mycostatin Nilstat Nystex Generic Lozenges oral suspension tablets Cream ointment powder Vaginal cream vaginal tablets Oropharyngeal candidiasis Cutaneous and mucocutaneous candidiasis Vulvovaginal candidiasis... 

From pharmacology results and proposed clinical program, select route of administration (oral, pulmonary, intramuscular, subcutaneous, transdermal, ocular, vaginal, buccal, sublingual, etc.) and formulation type to be dosed (solution, suspension, tablet, capsule, granulation powder, microspheres, microemulsion, depot drug, etc.). 

Vaginal tablets containing lactobacilli have been used in order to restore the normal vaginal flora. Formulation of these delivery systems requires specific proceedings in order to provide viability of lactobacilli and stability of the final product. Freeze drying of bacterial suspensions has been tested to obtain lyophilized powders for tablet production [81]. These powders were shown to be processable and tablet production was easy and reproducible. Also, the use of double-layer tablets (fast-release layer and slow-release layer) seems to be an interesting approach to lactobacilli administration. 

Multiple-unit powders for local application are preferably packaged in a dredger or a pressurized container (for skin, teeth, or vaginal douche use). These preparations consist of a dispersion of a solid phase (drug) in a liquid propellant (liquid phase). By action on the actuator, the suspension is released by gas pressure. The propellant in contact with ambient air is evaporated and the powder remains on the treated area. The particle size obtained depends on the powder particle size before the preparation of the suspension. 

Accepted in Europe as a food additive in certain applications. Included in the FDA Inactive Ingredients Guide (oral capsules, tablets and suspensions, topical suspensions, controlled release transdermal films and vaginal suppositories). Included in nonparenteral medicines licensed in the UK. Included in the Canadian List of Acceptable Non-medicinal Ingredients. 

Included in the FDA Inactive Ingredients Guide (oral capsules, suspensions, and tablets vaginal preparations). Included in nonparenteral medicines licensed in the UK. 

---